PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34381706-7	2021	Results: Compared with KEAP1/NFE2L2 wild-type, patients with KEAP1/NFE2L2 mutations were significantly associated with poorer overall survival (OS, HR = 1.97, 95% CI 1.48-2.63, P < 0.001) on atezolizumab and docetaxel (HR = 1.66, 95% CI 1.28-2.16, P < 0.001).	Docetaxel	208-217	NFE2 like bZIP transcription factor 2	Homo sapiens	67-73	
22387177-0	2012	NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.	Docetaxel	116-125	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4	
22387177-7	2012	Furthermore, NRF2 inhibition-mediated ErbB2 repression increases the sensitivity of these cells to docetaxel cytotoxicity and apoptosis.	Docetaxel	99-108	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17	
22387177-8	2012	The linkage between NRF2 and ErbB2 was confirmed in the ErbB2-positive breast cancer cell line BT-474: NRF2 knockdown suppressed ErbB2 expression and enhanced docetaxel sensitivity.	Docetaxel	159-168	NFE2 like bZIP transcription factor 2	Homo sapiens	20-24	
22387177-8	2012	The linkage between NRF2 and ErbB2 was confirmed in the ErbB2-positive breast cancer cell line BT-474: NRF2 knockdown suppressed ErbB2 expression and enhanced docetaxel sensitivity.	Docetaxel	159-168	NFE2 like bZIP transcription factor 2	Homo sapiens	103-107